Drug therapy - Ganciclovir

[31] DETECTION OF HERPESVIRUS DNA BY NESTED POLYMERASE CHITIN REACTION IN CEREBROSPINAL-FLUID OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS WITH NEUROLOGIC DISEASE - A PROSPECTIVE EVALUATION [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04): : 1087 - 1090

[32] PREVALENCE, PATHOPHYSIOLOGY, AND TREATMENT OF RHEGMATOGENOUS RETINAL-DETACHMENT IN TREATED CYTOMEGALOVIRUS RETINITIS [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1987, 103 (04) : 527 - 536

[33] GANCICLOVIR FOR LUMBOSACRAL POLYRADICULOPATHY IN AIDS [J]. LANCET, 1990, 335 (8680) : 48 - 49

[34] FULLER GN, 1992, J ACQ IMMUN DEF SYND, V5, pS33

[35] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1601 - 1607

[36] GRAVELEAU P, 1989, LANCET, V1, P511

[37] INTRANUCLEAR ACCUMULATION OF SUBGENOMIC NONINFECTIOUS HUMAN CYTOMEGALOVIRUS DNA IN INFECTED-CELLS IN THE PRESENCE OF GANCICLOVIR [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) : 1818 - 1823

[38] IDENTIFICATION OF THE LYTIC ORIGIN OF DNA-REPLICATION IN HUMAN CYTOMEGALOVIRUS BY A NOVEL-APPROACH UTILIZING GANCICLOVIR-INDUCED CHAIN TERMINATION [J]. JOURNAL OF VIROLOGY, 1990, 64 (12) : 6184 - 6195

[39] HARDY WD, 1991, J ACQ IMMUN DEF SYND, V4, pS22

[40] GANCICLOVIR FOR TREATMENT OF RENAL TRANSPLANT-ASSOCIATED PRIMARY CYTOMEGALO-VIRUS PNEUMONIA [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (01) : 187 - 190

[31] DETECTION OF HERPESVIRUS DNA BY NESTED POLYMERASE CHITIN REACTION IN CEREBROSPINAL-FLUID OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS WITH NEUROLOGIC DISEASE - A PROSPECTIVE EVALUATION [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04): : 1087 - 1090

[32] PREVALENCE, PATHOPHYSIOLOGY, AND TREATMENT OF RHEGMATOGENOUS RETINAL-DETACHMENT IN TREATED CYTOMEGALOVIRUS RETINITIS [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1987, 103 (04) : 527 - 536

[33] GANCICLOVIR FOR LUMBOSACRAL POLYRADICULOPATHY IN AIDS [J]. LANCET, 1990, 335 (8680) : 48 - 49

[34] FULLER GN, 1992, J ACQ IMMUN DEF SYND, V5, pS33

[35] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1601 - 1607

[36] GRAVELEAU P, 1989, LANCET, V1, P511

[37] INTRANUCLEAR ACCUMULATION OF SUBGENOMIC NONINFECTIOUS HUMAN CYTOMEGALOVIRUS DNA IN INFECTED-CELLS IN THE PRESENCE OF GANCICLOVIR [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) : 1818 - 1823

[38] IDENTIFICATION OF THE LYTIC ORIGIN OF DNA-REPLICATION IN HUMAN CYTOMEGALOVIRUS BY A NOVEL-APPROACH UTILIZING GANCICLOVIR-INDUCED CHAIN TERMINATION [J]. JOURNAL OF VIROLOGY, 1990, 64 (12) : 6184 - 6195

[39] HARDY WD, 1991, J ACQ IMMUN DEF SYND, V4, pS22

[40] GANCICLOVIR FOR TREATMENT OF RENAL TRANSPLANT-ASSOCIATED PRIMARY CYTOMEGALO-VIRUS PNEUMONIA [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (01) : 187 - 190